Increased T Lymphocyte Activation [PE] - N0000182157

Pharmacologic Class Information

Pharmacologic Code N0000182157
Pharmacologic Name Increased T Lymphocyte Activation
Pharmacologic Uses
  • CD19-directed genetically modified autologous T-cells
  • human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
Pharmacologic Concept Physiologic Effects - [PE]
Pharmacologic Concept Description This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept.

NDC Products with Increased T Lymphocyte Activation

The following table contains 5 products whose active ingredient are classified under the same pharmacologic class Increased T Lymphocyte Activation [PE].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0003-2327Yervoy Non-Proprietary Name: IpilimumabInjectionIntravenousE.r. Squibb & Sons, L.l.c.ACTIVE
0003-2328Yervoy Non-Proprietary Name: IpilimumabInjectionIntravenousE.r. Squibb & Sons, L.l.c.ACTIVE
0078-0846Kymriah Non-Proprietary Name: TisagenlecleucelInjection, SuspensionIntravenousNovartis Pharmaceuticals CorporationACTIVE
0078-0958Kymriah Non-Proprietary Name: TisagenlecleucelInjection, SuspensionIntravenousNovartis Pharmaceuticals CorporationACTIVE
71287-119Yescarta Non-Proprietary Name: Axicabtagene CiloleucelSuspensionIntravenousKite Pharma, Inc.ACTIVE